Press Release



Santen Publishes its Annual Integrated Report "Santen Report 2022"

October 14, 2022, Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; hereinafter "Santen") today announced the release of the "Santen Report 2022" (Integrated Report for the fiscal year ended March 31, 2022) in both English and Japanese versions, comprehensively covering both financial and non-financial information. Based on dialogue with a range of stakeholders, the report sets out Santen's management policy—which has been formulated from a long-term perspective to work toward value creation—and describes progress on strategic initiatives in Santen's medium-term management plan (MTP2025), towards realization of Santen's long-term vision Santen 2030. The report can be accessed on Santen's investor relations website (https://www.santen.com/en/ir/document/annual.jsp).

As a company specializing in eye health, Santen aspires to create a world where each person can live their happiest life through the best vision experience. Santen will continue to help reduce the loss of social and economic opportunities resulting from eye conditions by providing solutions in ophthalmology, by promoting people to pursue eye wellness and by creating a society that is inclusive regardless of visually impaired. Santen will continue to engage constructively with stakeholders while working to enhance corporate value through realizing "Happiness with Vision."



Happiness with Vision



Overview of Santen Report 2022:

The World We Aspire To

- Santen's value creation story, including the creation of products and services in ophthalmology, contributions to the development of ophthalmology, solutions of eye-related social issues, and sustainable corporate growth
- Progress toward KPIs of ESG (Environment, Society and Governance) Materiality

Strategy to Increase Corporate Value

Messages from Takeshi Ito, President and CEO, and Kazuo Koshiji, Chief Financial Officer &

Chief Risk Officer, explaining our approach to profitability improvement, risk identification and other current initiatives

 In addition to the business environment and strengths of each region in the execution of our strategy, introducing the sources of strength of our Japanese business and measures for further growth, and our EMEA (Europe, Middle East and Africa) business, which continues on a steady growth trajectory

 The product development pipeline and digital transformation that will support medium- to longterm growth

Environment and Society

- Our efforts to improve access to medical care and a feature article on our thoughts on creating a truly inclusive society as told by healthcare professionals
- · Our human resource strategy and human resource development initiatives for sustainable growth
- Environmental initiatives, including the Task Force on Climate-related Financial Disclosures (TCFD), which we endorsed in June

Corporate Governance

 Messages from the Chairman of the Board of Directors and newly appointed Directors of the Board and Corporate Auditor, and a discussion on efforts to create an effective Board of Directors in alignment with the business environment

Some parts of the report are also available in audio format by using AI (artificial intelligence) to enable wider accessibility, including by those with vision impairment.

About Santen

As a specialized company dedicated to eye health, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in over 60 countries and regions. Toward realizing "WORLD VISION" (Happiness with Vision), the world Santen ultimately aspires to achieve, as a "Social Innovator," Santen aims to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around the world. With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society.

For more information, please visit Santen's website (https://www.santen.com/en/).

Contact

Corporate Communications
Santen Pharmaceutical Co., Ltd.

E-mail: communication@santen.com